Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of BTRX-246040 in Parkinson's Disease with Motor Fluctuations
NCT03608371Phase 2Completed
- Sponsor
- BlackThorn Therapeutics
- Start
- Aug 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LY2940094 in Parkinson's disease (PD), sponsored by BlackThorn Therapeutics. Started Aug 2018; status: completed.
02
Drugs
LY2940094
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03608371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03608371.